{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T02:07:51Z","timestamp":1786327671332,"version":"build-2736575974"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s00415-025-13036-w","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T12:21:44Z","timestamp":1745497304000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Added value of optic nerve lesions for multiple sclerosis diagnostic criteria"],"prefix":"10.1007","volume":"272","author":[{"given":"Nima","family":"Mahmoudi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius","family":"Renne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz Felix","family":"Konen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin Fritz","family":"Jendretzky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"M\u00f6hn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Grote-Levi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Gingele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin W.","family":"H\u00fcmmert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Schwenkenbecher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Soldatov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt-Wolfram","family":"S\u00fchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Skripuletz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9298-2897","authenticated-orcid":false,"given":"Mike P.","family":"Wattjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"key":"13036_CR1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1056\/NEJMra1401483","volume":"378","author":"DS Reich","year":"2018","unstructured":"Reich DS, Lucchinetti CF, Calabresi PA (2018) Multiple Sclerosis. N Engl J Med 378:169\u2013180","journal-title":"N Engl J Med"},{"key":"13036_CR2","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17:162\u2013173","journal-title":"Lancet Neurol"},{"key":"13036_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S1474-4422(13)70259-X","volume":"13","author":"AT Toosy","year":"2014","unstructured":"Toosy AT, Mason DF, Miller DH (2014) Optic neuritis. Lancet Neurol 13:83\u201399","journal-title":"Lancet Neurol"},{"key":"13036_CR4","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/S1474-4422(22)00200-9","volume":"21","author":"A Petzold","year":"2022","unstructured":"Petzold A, Fraser CL, Abegg M et al (2022) Diagnosis and classification of optic neuritis. Lancet Neurol 21:1120\u20131134","journal-title":"Lancet Neurol"},{"key":"13036_CR5","first-page":"135245852312258","volume":"19","author":"A Vidal-Jordana","year":"2024","unstructured":"Vidal-Jordana A, Sastre-Garriga J, Tintor\u00e9 M, Rovira \u00c0, Montalban X (2024) Optic nerve topography in multiple sclerosis diagnostic criteria: existing knowledge and future directions. Mult Scler 19:13524585231225848","journal-title":"Mult Scler"},{"key":"13036_CR6","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/S1474-4422(15)00393-2","volume":"15","author":"M Filippi","year":"2016","unstructured":"Filippi M, Rocca MA, Ciccarelli O et al (2016) MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol 15:292\u2013303","journal-title":"Lancet Neurol"},{"key":"13036_CR7","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S1474-4422(21)00095-8","volume":"20","author":"MP Wattjes","year":"2021","unstructured":"Wattjes MP, Ciccarelli O, Reich DS et al (2021) 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol 20:653\u2013670","journal-title":"Lancet Neurol"},{"key":"13036_CR8","unstructured":"Montalban X. 2024 revisions of the McDonald criteria. Presented at ECTRIMS Copenhagen, 18-SEP-2024"},{"key":"13036_CR9","doi-asserted-by":"publisher","first-page":"e1130","DOI":"10.1212\/WNL.0000000000006207","volume":"91","author":"WJ Brownlee","year":"2018","unstructured":"Brownlee WJ, Miszkiel KA, Tur C, Barkhof F, Miller DH, Ciccarelli O (2018) Inclusion of optic nerve involvement in dissemination in space criteria for multiple sclerosis. Neurology 91:e1130\u2013e1134","journal-title":"Neurology"},{"key":"13036_CR10","doi-asserted-by":"publisher","first-page":"e482","DOI":"10.1212\/WNL.0000000000011339","volume":"96","author":"A Vidal-Jordana","year":"2021","unstructured":"Vidal-Jordana A, Rovira A, Arrambide G et al (2021) Optic nerve topography in multiple sclerosis diagnosis: the utility of visual evoked potentials. Neurology 96:e482\u2013e490","journal-title":"Neurology"},{"issue":"1","key":"13036_CR11","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207805","volume":"102","author":"A Vidal-Jordana","year":"2024","unstructured":"Vidal-Jordana A, Rovira A, Calderon W et al (2024) Adding the optic nerve in multiple sclerosis diagnostic criteria: a longitudinal, prospective, multicenter study. Neurology 102(1):e200805","journal-title":"Neurology"},{"key":"13036_CR12","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1093\/brain\/awz144","volume":"142","author":"M Filippi","year":"2019","unstructured":"Filippi M, Preziosa P, Banwell BL et al (2019) Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines. Brain 142:1858\u20131875","journal-title":"Brain"},{"key":"13036_CR13","first-page":"79","volume":"21","author":"H Reiber","year":"2003","unstructured":"Reiber H (2003) Proteins in cerebrospinal fluid and blood: barriers, CSF flow rate and source-related dynamics. Restor Neurol Neurosci 21:79\u201396","journal-title":"Restor Neurol Neurosci"},{"key":"13036_CR14","first-page":"99","volume":"4","author":"H Reiber","year":"1998","unstructured":"Reiber H (1998) Cerebrospinal fluid\u2013physiology, analysis and interpretation of protein patterns for diagnosis of neurological diseases. Mult Scler 4:99\u2013107","journal-title":"Mult Scler"},{"key":"13036_CR15","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.3389\/fimmu.2019.01110","volume":"10","author":"MW H\u00fcmmert","year":"2019","unstructured":"H\u00fcmmert MW, Wurster U, B\u00f6nig L et al (2019) Investigation of oligoclonal IgG bands in tear fluid of multiple sclerosis patients. Front Immunol 10:1110","journal-title":"Front Immunol"},{"key":"13036_CR16","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1093\/clinchem\/41.2.256","volume":"41","author":"H Reiber","year":"1995","unstructured":"Reiber H (1995) External quality assessment in clinical neurochemistry: survey of analysis for cerebrospinal fluid (CSF) proteins based on CSF\/serum quotients. Clin Chem 41:256\u2013263","journal-title":"Clin Chem"},{"key":"13036_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10633-016-9553-y","volume":"133","author":"JV Odom","year":"2016","unstructured":"Odom JV, Bach M, Brigell M et al (2016) ISCEV standard for clinical visual evoked potentials: (2016 update). Doc Ophthalmol 133:1\u20139","journal-title":"Doc Ophthalmol"},{"key":"13036_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.52170","author":"MA Foster","year":"2024","unstructured":"Foster MA, Pontillo G, Davagnanam I et al (2024) Improving criteria for dissemination in space in multiple sclerosis by including additional regions. Ann Clin Transl Neurol. https:\/\/doi.org\/10.1002\/acn3.52170","journal-title":"Ann Clin Transl Neurol."},{"key":"13036_CR19","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1177\/13524585231209016","volume":"29","author":"L Amezcua","year":"2023","unstructured":"Amezcua L, Robers MV, Soneji D et al (2023) Inclusion of optic neuritis in dissemination in space improves the performance of McDonald 2017 criteria in Hispanic people with suspected multiple sclerosis. Mult Scler 29:1748\u20131754","journal-title":"Mult Scler"},{"key":"13036_CR20","doi-asserted-by":"publisher","first-page":"e784","DOI":"10.1212\/WNL.0000000000207507","volume":"101","author":"G Bsteh","year":"2023","unstructured":"Bsteh G, Hegen H, Altmann P et al (2023) Diagnostic performance of adding the optic nerve region assessed by optical coherence tomography to the diagnostic criteria for multiple sclerosis. Neurology 101:e784\u2013e793","journal-title":"Neurology"},{"issue":"10","key":"13036_CR21","doi-asserted-by":"publisher","first-page":"188","DOI":"10.3389\/fneur.2019.00188","volume":"15","author":"P Schwenkenbecher","year":"2019","unstructured":"Schwenkenbecher P, Wurster U, Konen FF, Gingele S, S\u00fchs KW, Wattjes MP, Stangel M, Skripuletz T (2019) Im-pact of the McDonald criteria 2017 on early diagnosis of relapsing-remitting multiple sclerosis. Front Neurol 15(10):188","journal-title":"Front Neurol"},{"issue":"3","key":"13036_CR22","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209677","volume":"103","author":"J Sastre-Garriga","year":"2024","unstructured":"Sastre-Garriga J, Vidal-Jordana A, Toosy AT et al (2024) Value of optic nerve MRI in multiple sclerosis clinical management: a MAGNIMS position paper and future perspectives. Neurology 103(3):e209677. https:\/\/doi.org\/10.1212\/WNL.0000000000209677","journal-title":"Neurology"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13036-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13036-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13036-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T12:41:21Z","timestamp":1747658481000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13036-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["13036"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13036-w","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,24]]},"assertion":[{"value":"9 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N. Mahmoudi has nothing to disclose. J. Renne has nothing to disclose. F. Konen received travel compensation from Merck, Novartis, BMS and Alexion and is a German Research Foundation (DFG)\u2013funded fellow as part of the Clinician Scientist Program (PRACTIS) at Hannover Medical School. KF Jendretzky received research support from Else Kr\u00f6ner Fresenius Foundation and travel compensation and congress fee from Merck, Neuraxpharm and Novartis. N. M\u00f6hn received speaker honoraria from Alexion, Biogen, Novartis, and Merck as well as travel compensation from CLS Behring, Merck, and BMS. She is a German Research Foundation (DFG)\u2013funded fellow as part of the Clinician Scientist Program (PRACTIS) at Hannover Medical School. L. Grote-Levi is a German Research Foundation (DFG)\u2013funded fellow as part of the Clinician Scientist Program (PRACTIS) at Hannover Medical School. S. Gingele reports research support from Alnylam Pharmaceuticals, CSL Behring, Else Kr\u00f6ner Fresenius Foundation, Deutsche Forschungsgemeinschaft and Hannover Biomedical Research School (HBRS) and consulting and\/or speaker honoraria from Alexion, Alnylam Pharmaceuticals, AstraZeneca, GSK, Pfizer and Merck all outside the submitted work. M.W. H\u00fcmmert received institutional research support from Myelitis e. V., German Federal Joint Committee\/Innovation Fund, and NEMOS e. V., Speaker honoraria from selpers og, AMGEN\/Horizon, and Alexion, and travel grants from Alexion and compensation for serving on an advisory board from Alexion and Roche. P. Schwenkenbecher has nothing to disclose. A. Soldatov has nothing to disclose. K.W. S\u00fchs reports honoraria for lectures or travel reimbursements for attending meetings from Biogen, Merck, Mylan, Roche, Bavarian Nordic, Viatris and Bristol-Myers Squibb as well as research support from Bristol-Myers Squibb. T. Skripuletz reports research support from Alnylam Pharmaceuticals, CSL Behring, Novartis, Siemens; honoraria for lectures and travel expenses for attending meetings from Alexion, Alnylam Pharmaceuticals, argenx, Bayer Vital, Biogen, Bristol Myers Squibb, Celgene, Centogene, CSL Behring, Euroimmun, Grifols, Hexal AG, Horizon, Janssen-Cilag, Merck Serono, Novartis, Pfizer, Roche, Sanofi, Siemens, Swedish Orphan Biovitrum, Teva, Viatris; consultant fees from Alexion, Alnylam Pharmaceuticals, Biogen, Centogene, CSL Behring, Grifols, Hexal AG, Janssen-Cilag, Merck Serono, Novartis, Roche, Sanofi, Swedish Orphan Biovitrum, Viatris. M.P. Wattjes received speaker or consultancy honoraria from Bayer Healthcare, Biogen, Biologix, Bristol Myers Squibb, Celgene, Genilac, Imcyse, IXICO, Icometrix, Medison, Merck-Serono, Novartis, Roche, Spinger Healthcare, Sanofi-Genzyme.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"358"}}